ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

计划入组 174 人 · 首次发布于 2019 年 8 月 22 日

A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors

计划入组 10 人 · 首次发布于 2024 年 3 月 29 日

Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors

计划入组 156 人 · 首次发布于 2021 年 7 月 22 日

ATR-120

ATR inhibitors(Easton)

dual ATR/HDAC inhibitor (cancer)

Astron Corp Ltd

United States

Corvus Pharmaceuticals

United States

Kura Oncology

United States

Repare Therapeutics' ATR Inhibitor Camonsertib Shows Promise in DNA Repair-Deficient Cancers

Rakovina Therapeutics Advances Novel AI-Discovered PARP1 and ATR Inhibitors for Hard-to-Treat Cancers

Aprea Therapeutics Expands Global Patent Portfolio for WEE1 and ATR Precision Oncology Programs